Sankala Group’s Pfizer PFE Stock Holding History

Sankala Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-36	Closed	-$977	–	582
2026 Q2	$977	Hold	36	–	–	﹤0.01%	550
2026 Q1	$981	Hold	36	–	–	﹤0.01%	526
2025 Q4	$990	Buy	+36	New	+$908	﹤0.01%	541

Other funds holding PFE

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Sankala Group's PFE Position: Q3 2026 in Review

Sankala Group sold out of Pfizer (PFE) in Q3 2026, closing a stake of 36 shares — an estimated $977 sold.

Sankala Group first reported a position in PFE in Q4 2025 and held it in 3 quarters. The position peaked at $990 in Q4 2025. 1,829 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

Sankala Group reported no remaining Pfizer position as of Q3 2026 after selling out during the quarter.
Sankala Group sold 36 Pfizer shares in Q3 2026, an estimated $977.
Sankala Group first reported a position in Pfizer in Q4 2025 and held it in 3 quarters.
Sankala Group's Pfizer position peaked at $990 in Q4 2025.
1,829 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Sankala Group's 13F filing for Q3 2026, filed 9 Nov 2026.